| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -62.4 | -21.6 |
| EPS (diluted, $ a share) | $-1.29 | $-0.63 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: MBX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
MBX Biosciences, Inc.: key numbers
- Share price
- $53.10Close, Nov 17
- Market cap
- $2.64B
- Shares outstanding
- 49.66MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from MBX Biosciences, Inc.
All →MBX Biosciences Chairman, President and CEO Steven L. Hoerter Sells $268K of Stock
Steven L. Hoerter, Chairman, President and CEO, sold 4,893 shares of MBX Biosciences, Inc. at $54.82 a share, worth $268K in total on Nov 10, 2026. Shares held after the trade: 78,045 (-5.9%).
- Value
- $268K
- Shares
- 4,893
- Price
- $54.82
- Role
- Chairman, President and CEO
- Holding change
- -5.9%
- Trade date
- Nov 10, 2026
MBX Biosciences Financial Results
MBX Biosciences reported third quarter 2026 financial results, highlighting the initiation of its pivotal Phase 3 oPTimize trial for canvuparatide in hypoparathyroidism. The company ended the quarter with $481.6 million in cash and investments, which is expected to fund operations into 2029.
- Term
- Q3 2026
“The third quarter marked an important milestone for MBX with the initiation of our pivotal Phase 3 oPTimize trial of once-weekly canvuparatide, a potential best-in-class PTH replacement therapy.”
Steve Hoerter, Chairman and Chief Executive Officer
“With a strong balance sheet and cash runway into 2029, we believe we are well positioned to advance canvuparatide through pivotal development while continuing to invest in our growing obesity portfolio.”
Steve Hoerter, Chairman and Chief Executive Officer
MBX Biosciences CMO Salomon Azoulay Sells $20.1K of Stock
Salomon Azoulay, CMO, sold 373 shares of MBX Biosciences, Inc. at $53.96 a share, worth $20.1K in total on Nov 4, 2026. Shares held after the trade: 14,026 (-2.6%).
- Value
- $20.1K
- Shares
- 373
- Price
- $53.96
- Role
- CMO
- Holding change
- -2.6%
- Trade date
- Nov 4, 2026
MBX Biosciences Executive Compensation
MBX Biosciences appointed Peter Radovich to its Board of Directors as a Class I director, effective October 20, 2026. In connection with his appointment, Mr. Radovich received an initial grant of non-qualified stock options for 18,200 shares and will receive cash compensation according to the company's non-employee director compensation policy.
- Counterparty
- Peter Radovich